|RNS Reach Story|
|Go to market news section|
Amphion Innovations plc
Amphion Partner Company, Motif BioSciences announces drug discovery partnership with Jubilant Biosys Limited
London and New York, 5 December 2012 - Amphion Innovations plc (LSE: AMP), announces the formation of a partnership between Amphion Partner Company, Motif BioSciences Inc., the drug discovery engine for the pharmaceutical industry, and Jubilant Biosys Limited, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd. This partnership will facilitate the development of Best in Class drug candidates for licensing to pharmaceutical and biotechnology companies. Motif is staffed by a team of senior drug discovery executives who have developed major new drug classes at the world's leading pharmaceutical companies. Jubilant Biosys Limited is a global drug discovery and development company with a track record of successful collaboration with major pharmaceutical and biotechnology companies.
Motif and Jubilant have built a drug discovery plan on a de-risked research approach, focusing on mechanisms and First in Class drugs which have already established proof of their efficacy in man, and leveraging the expertise of Motif in medicinal chemistry and the infrastructure and experience of Jubilant to develop proprietary Best in Class drug candidates. Under the partnership, Jubilant will conduct the biology and chemistry for the program on a risk sharing basis.
Zaki Hosny, Chief Executive Officer of Motif said, "We are delighted to have formed this partnership with Jubilant. The traditional drug discovery model is changing rapidly as the large companies are relying increasingly on licensed in compounds to fill their pipelines. We believe that this environment is rich in opportunity for focused and nimble players such as Motif. We are confident that the combined experience and resources of Motif and Jubilant will prove to be a highly productive discovery engine for the pharmaceutical industry."
Subir Basak, President of Jubilant Biosys and Chemsys added, "We are pleased to be partnering with Motif to focus on developing Best in Class leads and pre clinical candidates for MRSA and Over Active Bladder, both areas of major unmet medical need with significant commercial potential."
For further information please contact:
+1 212 210 6224
Tim Robertson / Tom Horseman
+44 (0)20 7930 0777
Seymour Pierce Limited, Nominated Advisor
Mark Percy (Corporate Finance)
David Banks (Corporate Broking)
+44 (0)20 7107 8000
About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
Motif BioSciences, Inc. is applying proprietary technology and expertise in medicinal chemistry, biology and drug discovery to discover and develop best-in-class small molecule drugs that can be partnered out to the pharmaceutical industry for further development. Motif is a portfolio company of Amphion Innovations plc. www.motifbio.com
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
|©London Stock Exchange plc. All rights reserved|